MARLBOROUGH, Mass.,
Aug. 2, 2018 /PRNewswire/ -- RXi Pharmaceuticals
Corporation (NASDAQ: RXII) a biotechnology company developing
the next generation of immuno-oncology therapeutics based on its
proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform,
announced today that the European Patent Office (EPO) and Japan
Patent Office (JPO) have granted patents for the Company's novel
self-delivering RNAi (sd-rxRNA®) therapeutic platform. The
EPO Patent #: 2949752 B1 and JPO Patent #: 620309 cover composition
of matter, specifically structural and chemical attributes of
sd-rxRNA. These patents will be set to expire in 2029.
Logo -
http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
"We are pleased that both the European and Japan Patent offices
have recognized our novel therapeutic platform with the granting of
these patents," said Dr. James Cardia, Vice President of Business
Operations at RXi Pharmaceuticals. He further added, "The
Company recently reported the successful outcomes from both our
dermatology and ophthalmology clinical trials where our lead
candidate RXI-109, an sd-rxRNA therapeutic compound targeting
connective tissue growth factor (CTGF), is being evaluated.
We announced earlier this year that we would exclusively focus on
developing the next generation of immuno-oncology therapeutics
based on our self-delivering RNAi therapeutic platform. As
such, we are actively seeking to partner or out-license both the
Dermatology and Ophthalmology Franchises. The granting of these
patents further provides for multiple commercial and development
opportunities with RXI-109 and RXi's sd-rxRNA technology platform,
each broadly protected in the United
States and International regions."
About RXi's Proprietary Self-delivering RNAi (sd-rxRNA)
Technology Platform
RXi is a leader in the development of RNAi therapeutics that
have the ability to selectively block the expression of any target
in the genome, thus providing applicability to a broad spectrum of
therapeutic areas. Scientists at RXi have designed
chemically-modified RNAi compounds with improved drug-like
properties that are potent, stable and specific. These proprietary
compounds have built-in delivery properties and therefore do not
require a delivery vehicle for local therapeutic applications. The
enhanced properties of sd-rxRNA include efficient spontaneous
cellular uptake, stability, reduced potential for immune
stimulation, and potent, long-lasting intracellular activity. All
cell types tested (primary, neuronal and non-adherent) internalize
sd-rxRNA compounds uniformly and efficiently, resulting in potent
and long-lasting silencing.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company developing the next generation of
immuno-oncology therapeutics based on its self-delivering RNAi
(sd-rxRNA®) therapeutic platform. The Company's discovery and
research efforts are focused on developing sd-rxRNA therapeutic
compounds to be used with an Adoptive Cell Transfer (ACT) approach.
This process uses immune cells, such as T-lymphocytes that are
isolated from the patient or retrieved from allogeneic immune cell
banks, and then expanded and in some cases processed to express
tumor-binding receptors. Our approach introduces a new and
important step in ex-vivo processing of the immune cells where
sd-rxRNA is used to eliminate the expression of immunosuppressive
receptors or proteins from the therapeutic immune cells, making
them less sensitive to tumor resistance mechanisms and thus
improving their ability to destroy the tumor cells. Essentially, we
aim to maximize the power of our sd-rxRNA therapeutic compounds by
weaponizing therapeutic immune effector cells to attack cancer and
ultimately provide patients battling terminal cancers with a
powerful new treatment option that goes beyond current treatment
modalities.
For additional information, visit the Company's website,
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are neither historical facts nor
assurances of future performance. These statements are based only
on our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements
as a result of a number of important factors, including the safety
and efficacy of our product candidates, future success of our
clinical trials and scientific studies, our ability to enter into
strategic partnerships and the future success of these strategic
partnerships, the availability of funds and resources to pursue our
research and development projects and general economic conditions.
Our Annual Report on Form 10-K and subsequent Quarterly Reports on
Form 10-Q include detailed risks under the caption "Risk Factors"
that may affect our business, results of operations and financial
condition. Readers are urged to review these risk factors and to
not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact RXi Pharmaceuticals Corporation
Tamara McGrillen
Tel: +1 508-929-3646
Email: tmcgrillen@rxipharma.com
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-granted-patents-for-sd-rxrna-technology-strengthening-intellectual-property-estate-in-europe-and-japan-300690988.html
SOURCE RXi Pharmaceuticals Corporation